These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 21747362)

  • 1. Members need only apply.
    Nat Biotechnol; 2011 Jul; 29(7):551. PubMed ID: 21747362
    [No Abstract]   [Full Text] [Related]  

  • 2. Shaping the future of safer innovative drugs in Europe.
    Mestres J; Bryant SD; Zamora I; Gasteiger J
    Nat Biotechnol; 2011 Sep; 29(9):789-90. PubMed ID: 21904315
    [No Abstract]   [Full Text] [Related]  

  • 3. Impossible fixes.
    Nat Biotechnol; 2010 Feb; 28(2):103. PubMed ID: 20139925
    [No Abstract]   [Full Text] [Related]  

  • 4. [Establishing ophthalmology in the research framework programs of the European Union].
    Scholl HP; Wheeler-Schilling TH; Zrenner E; Holz FG
    Ophthalmologe; 2006 Feb; 103(2):91-9. PubMed ID: 16437232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. European competition.
    Nat Mater; 2006 Nov; 5(11):839. PubMed ID: 17077838
    [No Abstract]   [Full Text] [Related]  

  • 6. In vogue with venture.
    Patou G
    Nat Biotechnol; 2011 Nov; 29(11):967-9. PubMed ID: 22175076
    [No Abstract]   [Full Text] [Related]  

  • 7. Europe provides 172m euro for research into innovative medicines.
    Watson R
    BMJ; 2011 Mar; 342():d1577. PubMed ID: 21393337
    [No Abstract]   [Full Text] [Related]  

  • 8. Europe joins UK open-access bid.
    Van Noorden R
    Nature; 2012 Jul; 487(7407):285. PubMed ID: 22810672
    [No Abstract]   [Full Text] [Related]  

  • 9. Open-minded to open innovation and precompetitive collaboration.
    Wagner JA
    Clin Pharmacol Ther; 2010 May; 87(5):511-5. PubMed ID: 20407451
    [No Abstract]   [Full Text] [Related]  

  • 10. Report: EuroBioFund first annual forum in Helsinki.
    Biotechnol J; 2007 Apr; 2(4):406-7. PubMed ID: 17407205
    [No Abstract]   [Full Text] [Related]  

  • 11. 2 billion euro IMI launched with European pharma.
    Hodgson J
    Nat Biotechnol; 2008 Jul; 26(7):717-8. PubMed ID: 18612274
    [No Abstract]   [Full Text] [Related]  

  • 12. Europe (against) for cancer.
    Lancet; 1990 Oct; 336(8722):1036. PubMed ID: 1977023
    [No Abstract]   [Full Text] [Related]  

  • 13. Europe fiddles while innovation burns.
    Frantz S
    Nat Rev Drug Discov; 2005 Sep; 4(9):704-5. PubMed ID: 16178115
    [No Abstract]   [Full Text] [Related]  

  • 14. [Should Belgian compliance to the Maastricht principles lead to the break-up of our social security system?].
    Grinberg G
    Bull Mem Acad R Med Belg; 1997; 152(2):141-4. PubMed ID: 9491635
    [No Abstract]   [Full Text] [Related]  

  • 15. EC grant helps counter Chechen refugee-camp closures.
    Parfitt T
    Lancet; 2004 Jan; 363(9403):136. PubMed ID: 14733195
    [No Abstract]   [Full Text] [Related]  

  • 16. [France in the European and International research landscape].
    Julkowska D
    Med Sci (Paris); 2018 May; 34 Hors série n°1():55-57. PubMed ID: 29911567
    [No Abstract]   [Full Text] [Related]  

  • 17. Spat over IMI funding and intellectual property.
    Sinha G
    Nat Biotechnol; 2011 Jun; 29(6):473. PubMed ID: 21654659
    [No Abstract]   [Full Text] [Related]  

  • 18. [France in the European cooperation for the technological evaluation of health products].
    Meyer F
    Med Sci (Paris); 2018 May; 34 Hors série n°1():57-59. PubMed ID: 29911568
    [No Abstract]   [Full Text] [Related]  

  • 19. Determinants of vaccine supply.
    Natl Bur Econ Res Bull Aging Health; 2011; (3):2-3. PubMed ID: 22207917
    [No Abstract]   [Full Text] [Related]  

  • 20. [Increased commercial financing of national Medical Product Agencies within the EU].
    Ramel B
    Lakartidningen; 2003 Jan; 100(5):338-9. PubMed ID: 12607381
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.